Closes $16.6 Million Offering - Ladenburg Thalmann

Drug Pipeline Expanding - Zachs Says - Consensus  Buy

Wall Street Research Report

Jaguar Health is expanding its pipeline day by day. This company has made enormous strides in developing its product line of drugs and health care products.  With $16 million in new cash on hand further build out is assured 

These shares have been consolidating building a solid base .
Over the past two weeks shares of JAGX have rallied from levels around $1.05 to current levels around $1.50. After testing resistance at the $1.45 level for a few days it broke through to the upside. ( SEE TECHNICAL ANALYSIS )

Buffetts Billions - 2019 He Made $18 Billion In 3 Stocks 

Serious investors should immediately place these shares on their BUY LIST . Three analysts rate this stock a buy with one rating JAGX A STRONG BUY 



HC Wainwright set a $10.00 price target on shares of Jaguar Health and gave the stock a “buy” rating in a research report on Tuesday, July 2nd.

Zacks: Jaguar Health Inc (NASDAQ:JAGX) Given Consensus Recommendation of "Buy" by Analysts

Shares of Jaguar Health Inc (NASDAQ:JAGX) have been assigned an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company. Jaguar Health’s rating score has declined by 100% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Brokers have set a one year consensus price objective of $10.00 for the company and are anticipating that the company will post ($5.61) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Jaguar Health an industry rank of 77 out of 256 based on the ratings given to related companies.

Several research firms recently commented on JAGX. . ValuEngine raised shares of Jaguar Health from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, HC Wainwright set a $10.00 price target on shares of Jaguar Health and gave the stock a “buy” rating in a research report on Tuesday, July 2nd.

JAGX traded down $0.08 during trading on Friday, hitting $1.10. The company had a trading volume of 710,900 shares, compared to its average volume of 381,041. The company has a market capitalization of $5.78 million, a PE ratio of -0.01 and a beta of 0.66. Jaguar Health has a one year low of $1.00 and a one year high of $175.00. The firm’s 50-day moving average price is $2.07 and its 200 day moving average price is $1.45. The company has a quick ratio of 0.24, a current ratio of 0.35 and a debt-to-equity ratio of 0.02.

Jaguar Health (NASDAQ:JAGX) last posted its quarterly earnings data on Tuesday, May 21st. The biotechnology company reported ($12.59) EPS for the quarter, beating the consensus estimate of ($13.29) by $0.70. The business had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $2.20 million. Jaguar Health had a negative net margin of 727.27% and a negative return on equity of 826.41%. Sell-side analysts forecast that Jaguar Health will post -6.07 earnings per share for the current year.

In other Jaguar Health news, Director James J. Bochnowski purchased 180,582 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were purchased at an average cost of $2.00 per share, with a total value of $361,164.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.81% of the company’s stock.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Zachs rates this stock a hold